Establishment of the measurement properties and clinical interpretation of the Family Reported Outcome Measure (FROM-16)

Shah, Rubina 2023. Establishment of the measurement properties and clinical interpretation of the Family Reported Outcome Measure (FROM-16). PhD Thesis, Cardiff University. Item availability restricted.

Preview	PDF - Accepted Post-Print Version Download (23MB) | Preview
	PDF (Cardiff University Electronic Publication Form) - Supplemental Material Restricted to Repository staff only Download (161kB)

Abstract

Chronic diseases impact the quality of life (QoL) of family members as well as patients. The Family Reported Outcome Measure (FROM-16) could be used to measure this family impact. This PhD study aims to validate FROM-16, transforming it into a robust clinical and research tool, that can also inform health economic appraisal of medical interventions. Descriptive score bandings give meaning to QoL assessment, allowing clinicians to make better-informed decisions. The FROM-16 score banding (0-1=no effect on family members; 2-8=small effect; 9-16=moderate effect;17-25=very large effect; 26-32=extremely large effect on family members) was created using an anchor-based method and data from 4,413 family members of UK patients, recruited online. A major obstacle to including family members' impact in health economic evaluation has been the lack of appropriate utility measures comparable to EQ-5D-3L. To address this gap, using data from 4,228 family members, FROM-16 was mapped to EQ-5D-3L to generate utility values using multinomial logistic regression and split-half validation. The algorithm now enables researchers to calculate EQ-5D health utility values from FROM-16 scores. For FROM-16 to measure the impact of a new intervention on family members, its sensitivity to change must be demonstrated. A study including 83 NHS patients and family members confirmed that the FROM-16 was responsive to change (paired samples t-test p < 0.05). The data from 100 family members were used to calculate the Minimal Clinically Important Difference (MCID). This benchmark to evaluate clinically significant improvement was estimated for FROM-16 as a score change of ‘four’ points using anchor and distribution-based methods. The FROM-16 was used in a global COVID-19 study demonstrating that family members of COVID-19 survivors (n=735) experienced a substantial QoL impact of their relative's COVID-19. This study confirmed the value of FROM-16 for use in a pandemic. Major new aspects of FROM-16 have now been successfully validated.

Item Type:	Thesis (PhD)
Date Type:	Completion
Status:	Unpublished
Schools:	Medicine
Date of First Compliant Deposit:	16 February 2024
Last Modified:	16 Feb 2024 16:24
URI:	https://orca.cardiff.ac.uk/id/eprint/166344

Actions (repository staff only)

Edit Item